Investors
Series D financing
In November 2024, Alentis raised $181.4 million in Series D financing, supported by a syndicate of top-tier biotech investors. The financing supports Alentis to develop a deep pipeline of CLDN1 targeted medicines for solid tumors.
The funding round was led by OrbiMed with co-leads Novo Holdings and Jeito Capital. New investors Frazier Life Sciences, Longitude Capital, Catalio Capital Management, Piper Heartland Healthcare Capital and Avego Bioscience Capital participated in the round. Significant backing was also received from existing investor RA Capital Management, along with support from Morningside Venture Investments, BB Pureos, BPI France, as well as other early institutional investors.
Current investor syndicate
Earlier financing rounds
In 2023, Alentis raised $105 million in a Series C financing round led by Jeito Capital together with Novo Holdings and RA Capital with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
The financing will support Phase II and Phase I program of Alentis’ lead investigational product ALE.F02 respectively as well as the CLDN1 platform development.
In 2021, Alentis closed a Series B financing round, raising $67 million. The round was led by Morningside Venture Investments and Jeito Capital supported by the Series A investors.
Alentis was founded in 2019 with a CHF 12.5 million Series A financing co-led by Swiss venture capital firms BioMedPartners and BB Pureos Bioventures, with additional investments from Bpifrance, Schroder Adveq, and the German High-Tech Gründerfonds.